OrthoPediatrics
Builds pediatric orthopedic implants, scoliosis systems, and bracing services.
Something off on this page? Send us feedback.
Profile
Sells child-specific orthopedic implants, instruments, braces, and clinical O&P services across trauma/deformity correction, scoliosis, and smaller sports medicine/other procedures. The business reports one segment, serves mostly U.S. demand, and reaches international markets through a pediatric-focused product and education channel.
Designs and sells pediatric orthopedic implants, instruments, braces, and clinical O&P services for children with orthopedic conditions. The portfolio is grouped around trauma and deformity correction, scoliosis, and smaller sports medicine/other procedure lines, with one operating and reportable segment.
Recent additions widened the same pediatric focus: ApiFix brought non-fusion scoliosis technology, MD Orthopaedics added Mitchell Ponseti clubfoot bracing, Pega Medical added Fassier-Duval trauma/deformity systems, and Boston O&P added specialty bracing and clinics.
Demand is concentrated in the U.S., with distribution also reaching more than 70 countries outside the U.S. The model depends on pediatric surgeon adoption, clinical education, specialized field coverage, regulated device quality, and integration of acquired bracing and clinic assets.
Company facts
Categories
Key statistics
Year to date +34.9% · Average volume (30d) 232.5K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 20, 2026 | BTIG | Reiterate | Buy | $23 | $29 |
| Aug 5, 2026 | Truist Financial | Target | $17 | $22 | |
| Aug 5, 2026 | Piper Sandler | Reiterate | Overweight | $22 | $25 |
| May 1, 2026 | Truist Financial | Target | $18 | $17 | |
| Apr 24, 2026 | Canaccord Genuity | Target | $24 | $25 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026Q2 FY26 | −$0.30 | −$0.26 | +14.0% | $68.2M | $70.5M | +3.4% | +6.85% |
| Apr 30, 2026Q1 FY26 | −$0.38 | −$0.42 | −10.5% | $58.3M | $59.4M | +1.8% | +3.78% |
| Feb 26, 2026Q4 FY25 | −$0.37 | −$0.26 | +29.7% | $60.2M | $61.6M | +2.4% | +7.76% |
| Oct 28, 2025Q3 FY25 | −$0.26 | −$0.24 | +7.7% | $59.3M | $61.3M | +3.3% | −2.66% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $52.4M | $61.1M | $61.3M | $61.6M | $59.4M | $70.5M | |
| Gross profit | $38.3M | $44.0M | $45.3M | $45.1M | $43.4M | $52.4M | |
| Operating income | −$11.0M | −$10.7M | −$4.9M | −$5.5M | −$8.3M | −$4.1M | |
| Net income | −$10.7M | −$7.1M | −$11.8M | −$10.1M | −$10.7M | −$7.2M | |
| Diluted EPS | −$0.46 | −$0.30 | −$0.50 | −$0.43 | −$0.45 | −$0.30 | |
| Gross margin | 73.0% | 72.1% | 73.9% | 73.2% | 73.1% | 74.3% | |
| Operating margin | -21.0% | -17.4% | -7.9% | -8.9% | -14.0% | -5.8% |
Fiscal years (4-quarter sums)FY21 $98.0M · FY22 $122.3M · FY23 $148.7M · FY24 $204.7M · FY25 $236.3M
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $45.9M · Total debt $91.6M · Total assets $511.4M · Shareholders' equity $343.6M
Dividends
No dividends on record.
Ownership
Shares outstanding 25.68M · Float 17.07M · 66.5% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Pritzker Jennifer N. · 10 percent owner | 6.86M | 26.72% | Form 4 | Aug 26, 2026 |
| Squadron Capital LLC · 10 percent owner | 6.86M | 26.72% | Form 4 | Aug 26, 2026 |
| Brown Advisory Inc | 1.68M | 6.54% | 13F | Aug 14, 2026 |
| BlackRock, Inc. | 1.27M | 4.96% | 13F | Aug 7, 2026 |
| Braidwell LP | 1.10M | 4.28% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 26, 2026 | Squadron Capital LLC | 10 percent owner | −18,000 | $24.28 |
| Aug 25, 2026 | Squadron Capital LLC | 10 percent owner | −16,300 | $24.74 |
| Aug 24, 2026 | Squadron Capital LLC | 10 percent owner | −4,000 | $25.75 |
| Aug 26, 2026 | Jennifer N. Pritzker | 10 percent owner | −18,000 | $24.28 |
| Aug 25, 2026 | Jennifer N. Pritzker | 10 percent owner | −16,300 | $24.74 |
Peers
- Johnson & Johnson
Broad DePuy Synthes overlap in trauma, spine, and sports
- Stryker
Major trauma, extremities, spine, and surgical-tech incumbent
- Medtronic
Spine implants, navigation, robotics, and enabling-tech rival
- Smith & Nephew (ADR)
Trauma, extremities, and sports medicine overlap via NYSE ADR
- Orthofix Medical
Direct limb reconstruction, spine, biologics, and 7D navigation overlap
- Globus Medical
Spine, trauma, limb reconstruction, and navigation competitor
- Enovis
Bracing, recovery, sports medicine, and reconstructive overlap
- Zimmer Biomet
Broad orthopedic incumbent with trauma, extremities, and sports lines
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| OrthoPediatrics | $23.65 | −0.17% | $607.5M | — | — | 2.4 | +15.4% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| Stryker | $334.18 | +1.06% | $126.77B | 34.3 | 20.6 | 4.9 | +9.4% |
| Medtronic | $91.58 | +0.42% | $116.78B | 24.5 | 15.3 | 3.2 | +9.9% |
| Smith & Nephew (ADR) | $28.72 | −0.93% | $12.17B | 19.2 | — | 1.9 | +3.7% |
| Orthofix Medical | $9.70 | 0.00% | $392.1M | — | — | 0.5 | +3.9% |
| Globus Medical | $85.02 | +2.47% | $11.19B | 21.3 | 16.2 | 3.6 | +5.9% |
| Enovis | $24.90 | +0.08% | $1.43B | — | 6.6 | 0.6 | +3.2% |
| Zimmer Biomet | $100.91 | −0.00% | $19.52B | 24.6 | 11.5 | 2.3 | +4.8% |
| Median | 24.5 | 15.8 | 2.8 | +5.4% |